Tina Tingting WANG

Dr. Wang received her PhD in Cancer Biology from National University of Singapore. She has over 20 years’ experience in the field of oncology in biopharmaceutical industry, clinical practice, and translational medical research. She is a pioneer driving the clinical development of both TCR-T and CAR-T cell therapies for cancers. Recently, she led Lion TCR to obtain U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) Application and Fast Track Designation for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surface antigen (HBsAg) specific TCR. This is the first Phase 1b/2 study that uses TCR-T cell therapy to treat HBV-related hepatocellular carcinoma. Previously, she has driven autologous CD30 CAR-T cell therapy into Phase 1 clinical trials by leading the US FDA IND clearance to treat non-Hodgkin lymphoma at Tessa Therapeutics. She also accumulated plenty expertise on commercializing medical product in Asia Pacific market. At Roche Diagnostics APAC, she led the Asia Pacific medical team for the successful launch of VENTANA PD-L1 assays. She published 20 original works in SCI peer-reviewed international journals for translational medical research in oncology.